ANL

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA. Key highlights of the presentation include: AN4035 demonstrated strong intracellular payload retention, driving nanomolar to picomolar cytotoxicity in CEACAM5-positive/RAS-addicted cancer cell lines, along with a potent bystander-killing effect AN4035 induced deep regression in CEACAM5-positive/RAS-addicted CDX and PDX models, achieving a 73% objective response rate in a patient-derived xenograft trial (N=26) AN4035 exhibited a favorable preliminary toxicology profile in cynomolgus monkeys Tricomplex pan-RAS(ON) inhibitors currently in clinical development have demonstrated encouraging efficacy; however, their therapeutic potential has been limited by presumably on-target, off-tumor toxicities, particularly in the skin and gastrointestinal tract. AN4035, Adlai Nortye’s novel CEACAM5-targeting antibody-drug conjugate (ADC), was specifically designed to address these limitations. By delivering a proprietary pan-RAS(ON) inhibitor payload directly to tumors, AN4035 aims to reduce systemic toxicities, widen the therapeutic window and enable rational combination therapies. “We are delighted that AN4035, our first-in-class CEACAM5-targeting ADC armed with our proprietary pan-RAS(ON) inhibitor payload, has been selected for an oral presentation at this prestigious conference,” said Archie Tse, MD, PhD, Head of Research and Development at Adlai Nortye. “We hypothesized that an ADC approach could overcome some of the limitations of pan-RAS(ON) inhibitors by focusing their activity within tumors, thereby improving efficacy while minimizing on-target, off-tumor toxicities. The encouraging preclinical results we have seen to date support this hypothesis and reinforce our belief that AN4035 could represent the next generation of therapies against RAS-addicted tumors --- either as stand-alone treatments or in rational combinations, especially for CEACAM5 overexpressing tumors such as colorectal cancer.” This recognition undersco...